AI powered predictive live imaging for next generation stem-cell and organoid based screening platforms

Europe's leadership in 21st-century medicine hinges on harnessing the potential of stem cells and organoids — yet critical bottlenecks remain: inherent variability, lengthy preparation and assessment workflows, and the absence of live measurement tools capable of tracking biological evolution in real time. This information is inaccessible through conventional approaches, where labeling is biologically disruptive, technically unfeasible, or regulatorily prohibited. PROPHESCI addresses these limitations by monitoring stem cell and organoid development in 2D and 3D through non-destructive, label-free live imaging — enabling real-time digital histopathology trained to quantify and predict current biological states and future developmental outcomes, providing access to cell fate trajectories, cellular composition, and drug response at cellular resolution without any labeling requirement. The project will constitute the largest correlative database to date, systematically linking label-free imaging to multi-omic readouts and feeding predictive AI models capable of identifying early phenotypic changes, guiding growth protocols, accelerating culture timelines, optimising batch selection, and predicting developmental trajectories in real time. PROPHESCI empowers EUROBIOIMAGING and OPENSCREEN with technologies at the convergence of biological imaging, predictive AI, and organoid biotechnology. Beyond its primary use cases in drug screening and bioproduction, the simplicity, scalability, and retrainability of the platform make it broadly relevant to any laboratory, biotech, or hospital working with Non-Animal Models — since all share the same fundamental challenges of reproducibility, efficiency, and phenotypic accessibility. Its societal impact spans regenerative medicine, personalised therapy, industrial bioproduction, and pharmaceutical development, putting Europe at the forefront of preclinical research.